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e Institut Universitari Dexeus, Barcelona, SpainReceived 25 August 2008; accepted 30 October 2008Abstract Legislation in individual member states of the European Union on human embryonic stem cell (hESC) research is as
divergent as the different cultural, ethical, and religious views on the issue. On the occasion of the public launch of the
European Human Embryonic Stem Cell Registry (hESCreg: www.hescreg.eu), a two-day symposium was held on 18 and 19
January 2008 in Berlin to offer participants an overview of state-of-the-art hESC research and legislation throughout Europe and
in selected regions of the world. Thirty leading scientists from Europe as well as from the United States, Japan, and Australia
reported on a range of aspects related to research on hESC and reviewed the key elements of the newly established hESCreg
database of hESC lines. In this article we summarize and complete the information on the current status of international hESC
regulation.
© 2008 Published by Elsevier B.V.hESCreg reflects European and international
pluralism
The European Human Embryonic Stem Cell Registry (hESCreg)
is an online database that provides a comprehensive source
of information on all human embryonic stem cell (hESC) lines
that have been derived within the European Union (EU) and
beyond (Borstlap, 2008; Sipp, 2008). It provides scientists⁎ Corresponding author. Fax: 0049 30 450 539 902.
E-mail address: joeri.borstlap@charite.de (J. Borstlap).
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1873-5061/$ – see front matter © 2008 Published by Elsevier B.V.
doi:10.1016/j.scr.2008.10.003and the public at large with optimal and free access to
several lines of information on hESC. Providers of hESC lines
are being registered to provide detailed characteristics of
the cell lines derived. Research groups and stem cell banks
can register to provide information on their research
projects. The minimum registration criteria encompass
information on the origin of the cell line and its availability,
its consented and traceable procurement, and genetic
information, as well as differentiation potential and analysis
of pluripotent marker expression. Additional information
includes details on culture conditions, further hESC markers,
and derivation information as well as regulatory and ethical
information (Borstlap and Kurtz, 2008; Borstlap et al., 2008).
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derived in the EU and Europe-associated countries (see
Table 2) and 302 hESC lines derived outside Europe. Some 49
additional lines are being registered through the U.K. Stem
Cell Bank aswell as 8 lines through the U.S. National StemCell
Bank (at WiCell).
Differing views in the individual EU member states are
reflected in a multitude of national legislations on stem cell
research (Bosch, 2005). Legislation usually applies to
procurement of embryos for research, preimplantation
genetic diagnostic techniques (PGD), and research on and
derivation of hESC lines from (a) supernumerary “IVF”
embryos, i.e., human embryos created for medically assisted
fertilization (IVF) that are no longer intended for clinical
use, and (b) embryos created for research, i.e., human
embryos created by IVF with donated gametes and not
intended to induce pregnancy. Creation of embryos by
somatic cell nuclear transfer (SCNT) is referred to here as
“therapeutic cloning.”Ethical guidelines in Europe
Despite the divergent hESC legislation in Europe, the ethical
concern in Europe is unifying. European countries in which
hESC research is allowed carry out experiments in accor-
dance with the following fundamental ethical principles and
human rights laws of the European Union: (1) personal
protection rights (protection of human life), (2) political
rights (e.g., no inappropriate state intervention), and (3)
social and economic rights. Research on hESC in Europe,
therefore, meets a number of basic rules and requirements:
scientific necessity and high-ranking research objectives,
urgency, social desirability, and primacy of personal well-
being and interests of the individual over the sole interests of
science and society. Furthermore, in countries where
research on hESC lines is allowed, it may be carried out on
hESC lines only if deemed necessary, if there are no valid
alternatives, and if the work is nonredundant.Table 1 Regulatory variations for embryonic stem cell research
Regulatory position on human embryonic stem
cell research
Countries
hESC research permitted Belgium, the Cz
Kingdom (the Cz
therapeutic clon
• Derivation of new hESC lines from
supernumerary IVF embryos permitted
• Therapeutic cloning permitted
hESC research permitted Denmark, France
• Derivation of new hESC lines from
supernumerary IVF embryos permitted
• Therapeutic cloning prohibited
hESC research permitted only with
imported hESC lines
Germany, Italy (
• Derivation of new hESC lines from
supernumerary IVF embryos prohibited
• Therapeutic cloning prohibited
For a geographical overview please see Fig. 1.hESC research and legislation in selected
European and Europe-associated countries
By 2001, only a few member states such as Great Britain,
Belgium, and Sweden had enacted specific laws on the use of
embryos for research, but by 2008 around 16 EU and Europe-
associated countries have introduced legislation to regulate
stem cell research. While many countries in Europe are
moving to enable stem cell research using embryo-derived
stem cells through new legislation, the situation regarding
the specific nature of regulation across Europe is still quite
complex (Table 1, Fig. 1).
The following sections describe the legal situation in the
EU and Europe-associated countries that are members of the
European human embryonic stem cell registry (see Table 2)
and from which delegates were provided with information on
hESC research legislation during the hESCreg launch sympo-
sium. The subsequent sections present the legal situation in
the United States and in the Asian-Pacific countries.
Belgium
In Belgium the Law on Research on Embryos in vitro from
2003 (Loi relatif à la recherche sur les embryons in vitro:
http://www.eshre.com/emc.asp?pageId=751) forbids the
creation of embryos for medical research unless the objec-
tive of the project cannot be achieved using supernumerary
IVF embryos. Research on supernumerary embryos is accep-
table if (a) it concerns research in the area of fertility,
sterility, organ and tissue transplantation, or prevention or
treatment of diseases; (b) the research is based on the latest
research methodologies; (c) the research is conducted at an
accredited facility at a university clinic for reproductive
medicine ormedical genetics; (d) the research is supervised by
a specialized physician or a scientist with necessary qualifica-
tions; (e) the age of the embryo is not greater than 14days; and
(f) the local ethics committee has approved. Therapeutic
cloning formedical research is allowed, reproductive cloning isin the EU and Europe-associated countries
ech Republic, Finland, Israel, Portugal, Spain, Sweden, United
ech Republic, Finland, and Portugal neither prohibit nor allow
ing by law)
, Hungary, the Netherlands, Norway, Switzerland
there is no specific law covering existing hESC lines in Italy)
Figure 1 The status of hESC research legislation throughout the EU and Europe-associated countries. The four colors represent the four
positions on hESC research in Europe: green, hESC research and derivation of hESC lines from supernumerary IVF embryos permitted (dark
green, therapeutic cloning permitted; light green, therapeutic cloning prohibited); orange, hESC research permitted only with imported
hESC lines—hESC derivation and SCNT prohibited; red, prohibition of any hESC research; grey, no hESC-specific legislation in place.
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embryonic stem cells for commercial purposes. The procure-
ment of and research on hESC from supernumerary IVF
embryos are allowed (Pennings, 2007). Major active research
sites are the Vrije Universiteit in Brussels and the Université
Libre de Bruxelles.
The Czech Republic
In the Czech Republic, hESC research is allowed by the Act on
Research on Human Embryonic Stem Cells (Zákon 227/2006:
http://www.eshre.com/emc.asp?pageId=998) from 2006
only if the research (a) brings about important knowledge
applicable to the development of new or improved diag-
nostics, prevention, or therapeutics in humans; (b) cannot be
solved by using animal models; and (c) is ethically accep-
table. PGD is permitted, although not yet treated by the law.
Therapeutic cloning for research purposes as well as for the
development of new therapies is not explicitly prohibited by
law and is subject to case-by-case decisions of the respective
institutional ethical bodies. In contrast, the Czech act clearly
prohibits any manipulation that could lead to the creation of
a new human individual, the so-called reproductive cloning.
hESC may be derived from supernumerary IVF embryos. hESC
lines on which research is performed must be listed in the
Czech central registry, which is open to the public. Two
institutions, one in Brno (Masaryk University) and one in
Prague (Institute of Experimental Medicine Academy of
Sciences of the Czech Republic), with around six research
groups are involved in hESC research.Denmark
In Denmark research is allowed on embryos if it can lead to
the improvement of IVF or PGD methods and the obtainment
of important new knowledge applicable to therapies for
human diseases. This is covered by the Act of Artificial
Fertilization from 1997 (Lov nr. 460 om kunstig befrugtning
som ændret ved: https://www.retsinformation.dk/Forms/
R0710.aspx?id=84963), which was updated in 2006 (Lov nr.
535 om kunstig befrugtning som ændret ved: https://www.
retsinformation.dk/Forms/R0710.aspx?id=10291). Embryo
research can be conducted within 14 days of embryo deve-
lopment after fertilization. From 2003 on, hESC can be pro-
cured from supernumerary IVF or PGD embryos. The Danish
law prohibits cloning procedures. Major research centers are
the Ciconia Aarhus Privathospital Højbjerg, the University of
Copenhagen, and the University of Southern Denmark at
Odense.
France
In France the Bioethics Law (Loi no. 2004-800 relative à la
bioéthique: http://www.legifrance.gouv.fr/affichSarde.do?
reprise=true&page=1&idSarde=SARDOBJT000007108472&or-
dre=null&g=ls) was last reviewed in 2004. Every 5 years the law
is revised by the French parliament, so the next time will be in
2009. The decree of February 2006 complemented the
Bioethics Law. Embryo research is allowed (a) if the proposed
research is expected to result in significant therapeutic gains
and no other efficient alternative method is available; (b) if
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issues and failed to be suitable for that purpose; (c) if both
parents have given written consent; (d) if the research proto-
col has been specifically approved by the ministries respon-
sible for research and health (competent authority: Agence de
la Biomedicine); and (e) if the embryo is destroyed within 7
days after fertilization. Both therapeutic cloning and repro-
ductive cloning are prohibited. Contraventions to the repro-
ductive cloning ban carry a penalty of up to 30 years
imprisonment and a fine of up to €7,500,000. The procurement
of hESC lines is allowed from supernumerary IVF embryos as
well as from those that have been identified as unsuitable for
implantation following preimplantation diagnosis. The first
French hESC line was derived in October 2007 from such a PGD
embryo carrying a monosomy 21 and a trisomy 1 (http://ist.
inserm.fr/basispresse/CPS/CPS2007anglais/23october2007.
pdf). To achieve the greatest possible transparency the
embryos and hESC lines used are registered. Currently hESC
research is authorized in around 34 authorized laboratories.
Finland
The Medical Research Act (Laki lääketieteellisestä tutkimuk-
sesta: http://www.finlex.fi/fi/laki/ajantasa/1999/
19990488) from 1999 forbids the production of embryos for
research purposes in Finland. However, embryos created byTable 2 EU and Europe-associated countries that are members o
and that have hESC-specific legislation in place
Country No. of hESC a Law/year
Belgium 24 Law on Resea
embryons in
Czech Republic 7 Act on Resea
Denmark 26 Act on Artific
ændret ved/
Lov nr. 535/2
France 1 Bioethics Law
No. 2006-126




Hungary hESC derivation not allowed Health Care A
Israel 15 Prohibition o
Modification
Italy hESC derivation not allowed Law on Medic
medicalment
Netherlands 4 Embryo Act/
Norway n.d. Biotechnolog
Portugal n.d. Law on Medic
2006; Opinio
Spain 10 Law on Biom
Sweden 67 Act on Stem
behandlingss
(Lag om gene
Switzerland 1 Stem Cell Re
United Kingdom 38 Human Fertil
Embryology B
n.d., not determined.
a Number of hESC lines derived that are registered in hESCreg as of Dtherapeutic cloning might not be considered embryos by law
(“living group of cells resulting from fertilization”) and could
possibly be procured. The research on such embryos is
allowed only for 14 days after fertilization, after which the
embryo has to be destroyed. Donated gametes have to be
used within 10 years. Gametes and ovarian tissue for the
patient’s own use can be stored in liquid nitrogen for an
unlimited period of time. There are no restrictions on
research with PGD embryos, nor on the procurement of and
research on hESC that have been derived from super-
numerary PGD or IVF embryos. Reproductive cloning and
the production of chimeras are prohibited by law. Research
centers are at the University of Helsinki, the University of
Tampere, the University of Turku, the University of Kuopio,
and the University of Oulu.
Germany
In April 2008, Germany amended its Stem Cell Act (Stamm-
zellgesetz: http://www.bmj.bund.de/enid/77e71f1a0cb444-
ca3eabd0cff43559fd,33d0e45f7472636964092d0933303334/
Menschenrechte/Bioethik_xb.html), which generally forbids
any use of hESC, but also grants certain exceptions to the law.
Researchers wishing to import or use hESC must submit an
application for license on a case-by-case basis. Imported hESC
lines must be derived from supernumerary embryos fromf the European Human Embryonic Stem Cell Registry (hESCreg)
rch on Embryos in vitro (Loi relatif à la recherché sur les
vitro)/2003
rch on Human Embryonic Stem Cells (Zákon 227/2006)/2006
ial Fertilization (Lov nr. 460 om kunstig befrugtning som
1997, Lov nr. 427/2003, Lov nr. 69/2004, Lov nr. 240/2004,
006
(Loi no. 2004-800 relative à la bioéthique)/2004, Decree
arch Act (Laki lääketieteellisestä tutkimuksesta)/1999
(Stammzellgesetz StZG)/2008
ct (CLIV/1997)
f Genetic Intervention Act (Human Cloning and Genetic
of Reproductive Cells)/1999, modified 2004
ally Assisted Reproduction (Norme in materia di procreazione
e assistita)/2004
2002; phase 2/2007
ical Act (Lov om humanmedisinsk bruk av bioteknologi)/2007
ally Assisted Procreation (Procriação medicamente assistida)/
n on Human Cloning (Parecer sobre clonagem humana)/2006
edical Research (Ley de Investigación Biomedical)/2007
Cell Research (Lag om åtgärder i forsknings-eller
yfte med ägg från människa)/1991, with changes in 2006
tisk integritet m.m.)
search Act (Stammzellengesetz)/2005
ization and Embryology Act/1990; Human Fertilization and
ill/2001 and 2008 (still under parliamentary review)
ecember 2008.
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before 1 May 2007; theymay not have been obtained following
PGD and the procurement of the cell lines must have been
compliant with the respective national legislation. Thirtyfour
licenses have been issued by the competent licensing
authority, the Robert-Koch Institute Berlin, in accordance
with the Central Ethics Committee for Stem Cell Research.
More than twenty research groups are active in hESC research.
Hungary
In Hungary, embryos cannot be created for research pur-
poses. Only embryos created in assisted reproductive
procedures can be used for research on the basis of the
decision of the Hungarian Reproduction Commission and as
regards the Health Care Act (CLIV/1997: www2.ohchr.org/
english/bodies/cescr/docs/E.C.12.HUN.3-Annex10.pdf).
Embryos on which experiments were carried out cannot be
implanted into the human body and cannot be kept alive for
more than 14 days. For the unique purpose of investigating
on the probable illness of the child to be born, separation of
the cells of the embryo is allowed. hESC derivation is not
allowed. With special permission from the Hungarian
Reproductive Council, which regulates all hESC work in
Hungary, the import of hESC is permitted. Licenses that were
given so far are few and up until now (as of December 2008)
only one research group is actively working with hESC lines.
Israel
Israel takes third place worldwide as regards publications of
research teams that have utilized hESC in research experi-
ments (Löser et al., 2008). In general, the public opinion in
Israel has been in favor of research on hESC. According to
Jewish law human life begins 40 days after the fusion of egg
and sperm cells and only when the embryo is within the
mother’s womb. With the view of the great therapeutic
potential of hESC the religious leaders in Israel support hESC
research. After thorough moral discussions at the Israeli
House of Parliament, the Prohibition of Genetic Intervention
Act (Human Cloning and Genetic Modification of Reproduc-
tive Cells: http://www.bibliojuridica.org/libros/5/2292/59.
pdf) from 1999, modified in 2004, allows therapeutic cloning
and the derivation of hESC lines from supernumerary IVF
embryos. Reproductive cloning is prohibited. Preimplanta-
tion genetic diagnosis is allowed in Israel. There is an Israeli
society for stem cell research (the Israel Stem Cell Society)
and a governmentally funded consortium of industrial and
academic partners for the development of cell therapy (the
Israeli Consortium for Cell Therapy, “Bereshith”). Active
hESC research laboratories are at the Hadassah University
Hospital Jerusalem, the Israel Institute of Technology Haifa,
the Hebrew University of Jerusalem, and other institutions.
Italy
In Italy the Law on Medically Assisted Reproduction (Norme in
materia di procreazione medicalmente assistita: http://
assemblealegislativa.regione.emilia-romagna.it/wcm/bib-
lioteca/apub/pbib/dossier/index/2005/procreazione_assis-
tita/normativa/legge_19febbraio_04.htm) from 2005prohibits the creation of embryos not only for research
purposes but also for experimentation. Clinical and basic
research is allowed when it is aimed at improving therapy and
diagnosis and protecting the health and development of the
embryo itself. Research on hESC is allowed only if alternative
methodologies are not available. As in Germany hESC lines
must be imported from other countries. Any cloning proce-
dures are prohibited.
The Netherlands
The Embryo Act (Embryowet: http://www.minvws.nl/en/
folders/ibe/2002/introduction-embryo-act.asp) from 2002
bans the creation of embryos for research purposes and
stem cell procurement in the Netherlands. The derivation of
hESC from supernumerary IVF embryos is possible if there are
no alternatives to embryonic stem cells for the purpose of the
research. To carry out hESC derivation or PGD each case must
be approved by the Central Committee for Research Involving
Human Subjects. As of 2008, two licenses to derive lines have
been granted (to the universities of Utrecht and Groningen)
and only the AZM, a teaching hospital from the University of
Maastricht, has been allowed to perform PGD. Therapeutic
cloning and the creation of chimeras are permanently
prohibited. This situation is unlikely to change until 2012.
Norway
Since the review of the Biotechnology Act from 2007 (Lov om
humanmedisinsk bruk av bioteknologi m.m.–bioteknologilo-
ven: http://www.lovdata.no/all/nl-20031205-100.html),
research on supernumerary embryos and PGD in Norway has
been allowed. The government has decided not to issue
licenses for PGD to Norwegian clinics. Patients can apply to
the Preimplantation Genetics Board (a new board appointed
by the government). If the board accepts the application, the
couple may be treated abroad and the expenses will be
covered by the health service. Stem cell procurement from
supernumerary IVF embryos for medical and biological
research and education is allowed as well. Cloning (thera-
peutic) and the use of techniques aimed at the production of
genetically identical individuals are prohibited. The act will
be reviewed every 4 years and amendments are expected in
June 2011.
Portugal
In Portugal the Law on Medically Assisted Procreation (Lei no.
32/2006 Procriação medicamente assistida: http://www.
dre.pt/pdfgratis/2006/07/14300.pdf ) from 2006 prohibits
the creation of embryos for research but allows research on
supernumerary IVF embryos or those with severe genetic
disorders. It is also permissive if the envisaged project will
benefit humankind and aims at prevention, diagnosis, or
therapy as well as the perfection of medically assisted repro-
duction techniques. Embryos that have not been created
through the fertilization of a human oocyte by a human
sperm, a condition that includes therapeutic cloning techni-
ques, might be allowed but only for research purposes. Law
32/2006 does not regulate therapeutic cloning. The National
Council of Ethics for the Life Sciences supports the idea of
106 A. Elstner et al.therapeutic cloning because of the potential therapeutic
benefits for human beings (Opinion on Human Cloning/2006
(http://www.cnecv.gov.pt/cnecv/pt/Pareceres/), which has
no legal implication). However, it recommends that research
should rather be focused on techniques that do not involve
nuclear somatic transfer and on somatic cell reprogramming
research. Reproductive cloning is prohibited. PGD is allowed.
Spain
While the Law on Biomedical Research from 2007 (Ley 14/
2007 de Investigación Biomédica: http://noticias.juridicas.
com/base_datos/Admin/l14-2007.html) in Spain prohibits
the creation of embryos for research purposes, it allows the
production of hESC for research or therapy using all the
currently available technologies such as therapeutic cloning,
reprogramming of somatic cells, and any other future
technique (Article 33 of the BMR Act). There is a nonprofit
national stem cell bank (BNLC) with branches in three
separate locations—Granada, Barcelona, and Valencia—with
the aim of guaranteeing availability and exchange of hESC
lines. Ten Spanish stem cell lines have been completely
characterized with respect to morphological, phenotypic,
microbiological, virological, molecular, and functional mar-
kers in vitro and in vivo by two research centers, the Center
of Regenerative Medicine in Barcelona and the Principe
Felipe Centro de Investigacion in Valencia.
Sweden
As early as 1991 the act concerning research on fertilized eggs
(Lag om åtgärder i forsknings-eller behandlingssyfte med ägg
från människa: http://www.notisum.se/rnp/sls/fakta/
a9910115.htm) in Sweden allowed research on embryos in
the first 14 days after fertilization (with most recent
amendments in 2006, Lag om genetisk integritet m.m.).
Since 2005 the Swedish Act on Embryo Research has
permitted the creation of embryos also by means of thera-
peutic cloning for medical research and stem cell procure-
ment. It also permits the donation of egg cells for research
purposes. PGD and research on embryos up to 14 days are
allowed. At least three centers are active in hESC research
and derivation of hESC lines. Cellartis AB in Gothenborg has
derived 37 hESC lines, the Karolinska Institute in Stockholm,
30. Another research institute is the Stem Cell Center Lund. It
has been reported that the first xeno-free hESC line in the
world was derived in Sweden in 2006 (Ellerström et al., 2006).
Switzerland
The Stem Cell Research Act (Stammzellenforschungsgesetz:
http://www.bag.admin.ch/themen/medizin/03301/03361/
03410/index.html?lang=fr) of Switzerland, which went into
force in 2005, prohibits the creation of embryos for research.
hESC may be obtained from supernumerary IVF embryos,
donated by informed consent, until the seventh day of their
development. hESC lines obtained from supernumerary IVF
embryos may also be imported from abroad for research
purposes and are subject to approval by the Federal Office of
Public Health. Imported hESC can be used for research if
obtained in the respective country according to the Swiss
legislation. Ethically approved research projects involvingESC are required. The cloning of human germ cells and
embryos is prohibited by law. PGD is not yet allowed but a
law project is in preparation. Research laboratories working
on ESC are in Geneva, Basel, and Bern (see also the Swiss
Stem Cell network: www.sscn.unige.ch).
The United Kingdom
In the United Kingdom the 2001 amendment to the Human
Fertilisation and Embryology Act (http://www.parliament.
the-stationery-office.co.uk/pa/ld200708/ldbills/006/
08006.i-iv.html), which became law in 1990, legalizes the
creation of embryos for medical research, including ther-
apeutic cloning and the derivation of hESC lines. PGD is
allowed. In the HFE bill that updates the HFE Act from 2008,
as of December 2008, the definition of an embryo now
includes embryos created by cloning and other processes.
Furthermore, it includes the permission for creation of
interspecies embryos for research. In addition to Sheffield,
London, Edinburgh, Newcastle, Manchester, Nottingham,
and Cambridge, there are 13 more geographic hESC research
centers and a central UK Stem Cell Bank at the National
Institute for Biological Standards and Control, South Mimms
(www.ukstemcellbank.org).
hESC research and legislation in the
United States
Eleven states, namely California, Connecticut, Illinois, Mary-
land, Massachusetts, New Jersey, New York, Rhode Island,
Wisconsin, Iowa, and Missouri support hESC research. The
first nine of these states supportive of hESC research have
come together to form the Interstate Alliance on Stem Cell
Research with the aim of improving scientific exchange,
coordination, and collaboration in the field. Several other
states ban or restrict hESC research. The common guidelines
in the supportive states are: (1) ethical and scientific over-
sight, (2) voluntary and informed consent, (3) donors are not
paid/reimbursed, and (4) transparency and public reporting.
These standards are influenced by the National Academy of
Sciences. In the United States, no federal funding is available
for the manufacture of new hESC or research into human
embryonic stem cells that were produced after 9 August
2001. It is possible to apply for funding for themanufacture of
pluripotent stem cells and research into human embryonic
stem cells with a production date prior to 9 August 2001. In
addition to the 21 NIH-registered available cell lines, a
further 17 cell lines may be obtained from Harvard University
and 4 from Stanford University (personal communication, S.
Stayn, Stanford University, Stanford, CA, USA, at hESCreg
launch symposium, Berlin, January 2008).
hESC research and legislation in the
Asia-Pacific region
The research centers in the Stem Cell Network of the Asia-
Pacific region (SNAP) are located in Australia, China, India,
Japan, Singapore, South Korea, and Taiwan (see Table 3).
SNAP was established in October 2007. Its aims are to
promote research into hESC in the region, to improve
international collaboration, and to offer exchange programs
Table 3 hESC research in the Asia-Pacific region
Country Major hESC research centers
Australia Australia Stem Cell Centre and
Monash University
China CAS (Beijing, Shanghai, Guangzhou)
India National Stem Cell Center (under
development, Bangalore)
Japan RIKEN CDB, national and private
universities (Kyoto, Tokyo, Keio)
Singapore A⁎STAR (IMCB, IMB), NUS
South Korea National Stem Cell Center, Seoul
National University
Taiwan Academia Sinica, National Yang
Ming University
The countries listed form the Stem Cell Network of the Asia-
Pacific Region (SNAP; personal communication, D. Sipp, hESCreg
launch symposium, Berlin, January 2008).
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of these countries has its own stem cell bank. To date,
clinical-grade stem cell lines are claimed to have been
produced by researchers in Singapore. Chinese researchers
are thought to have produced the highest number of stem
cell lines; the exact status of these lines is, however,
unverified. As of February 2008 scientists in the Asia-Pacific
region are thought to have produced a total of more than 215
hESC (personal communication, D. Sipp, RIKEN Center for
Developmental Biology, Japan, at hESCreg launch sympo-
sium, Berlin, January 2008). Of that number already 10 have
been proposed as clinical grade. In the countries of the Asia-
Pacific region researchers receive generous state funding.
Religious, political, or cultural limitations on hESC research
are practically nonexistent. However, many regions do not
have research and clinical governance traditions in the
European or North American mode, and efforts to coordinate
international collaboration and consistency are developing
(e.g., International Stem Cell Forum initiatives on stem cell
characterization and stem cell banking: www.stemcell-
forum.org).
Conclusion
Since there is no single universally accepted view on the
ethical, legal, and moral status of the embryo as such, nor on
the use of hESC lines derived thereof, one of the registry’s
tasks is to reflect European and international pluralism ade-
quately and provide appropriate methods of safeguarding
high standards in relation to ethical concerns and transpa-
rency in research. Eventually this may prevent the unneces-
sary development of new cell lines, avoid the duplication ofresearch work, and consolidate Europe’s position in the field.
hESCreg is already the most comprehensive registry of its
kind worldwide and will contribute to strengthening the role
of the European Union in embryonic stem cell research at the
international level. Consequently, the European Commission
has issued hESCreg with the mandate to act as the central
reference for all funding decisions on proposed hESC
research projects within the Commission’s Seventh Frame-
work Programme of the European Community for Research,
Technological Development and Demonstration Activities
(2007–2013). The registry is actively engaged in the societal
discourse on research into human embryonic stem cells, a
debate with direct impact on the next Framework Pro-
gramme after 2013.Acknowledgments
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